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Abstract 
Sinonasal undifferentiated carcinoma (SNUC) is a rare, poorly differentiated and aggressive 
malignancy of the nasal cavity and paranasal sinuses first reported by Frierson et al. in 1986 
with less than 300 known cases reported since then. Due to the rarity and aggressive nature of 
the disease, there is a lack of consensus regarding optimal management in these patients. 
Treatment decisions have mostly been guided by a small number of cases series and can vary 
widely between institutions. In this unique case presentation, we review a case of sinonasal 
undifferentiated carcinoma in a young Hispanic male reviewing the literature on a rare disease, 
in order to elucidate effective treatment options for improved future outcomes. Based off of 
literature review and prior case series, the multiple modality approach should result in the best 
possible outcome for this rare and aggressive disease. In this specific case of a young Hispanic 
male with Stage IVB SNUC, we proceeded with Neo-adjuvant TPF (Docetaxel, cisplatin and 
fluorouracil) with effective results, followed by Cisplatin and concurrent radiation once the 
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patient had interval progression, and was deemed unresectable. Given the rarity and complex-
ity of this disease, a prospective randomized controlled study should eventually be pursued to 
properly determine the most effective mode and combination of therapies. At this time treat-
ment can only be based on reported case series and a small number of retrospective studies, 
and therefore it is important to continue to evaluate different institutions’ methods of treat-
ment. © 2019 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Sinonasal undifferentiated carcinoma (SNUC) is a rare, poorly differentiated and aggres-
sive malignancy of the nasal cavity and paranasal sinuses first reported by Frierson et al. in 
1986 with less than 300 known cases reported since then [1, 2]. It has an estimated incidence 
of 0.02 per 100,000 [3]. Due to the rarity and aggressive nature of the disease, there is a lack 
of consensus regarding optimal management in these patients. Treatment decisions have 
mostly been guided by a small number of cases series and can vary widely between institu-
tions [4]. In this unique case presentation, we review a case of sinonasal undifferentiated car-
cinoma in a young Hispanic male reviewing the literature on a rare disease, in order to eluci-
date effective treatment options for improved future outcomes. 
Case Presentation 
Mr. T.V. is a 30-year-old Spanish speaking male with no significant past medical history, 
initially presenting to the ER with three weeks of right orbital and frontal headaches. His 
symptoms progressed to include right-sided ptosis, photophobia, nausea, vomiting, right-
sided facial numbness, and intermittent anosmia. He underwent imaging in the ER with a head 
CT which was significant for a 4.7 cm × 4.1 cm × 3.9 cm ethmoid/sphenoid sinus mass. ENT 
performed an urgent biopsy confirming a poorly differentiated malignant neoplasm with pos-
itive pankeratin staining, consistent with carcinoma (Fig. 3). Tumor cells were negative for 
markers of neuroendocrine differentiation and squamous differentiation. The patient was p63 
and EBV negative, with findings most consistent with sinonasal undifferentiated carcinoma. 
MRI Brain demonstrated a 5.2 cm AP T2-intermediate, enhancing, diffusion restricting mass 
centered in the ethmoid sinuses with extension into the nasal cavity, stenosis of bilateral or-
bital apices, encasement of bilateral optic nerves, and mass effect in the bilateral medial rectus 
muscles (Fig. 1). A CT chest/abdomen/pelvis was negative for metastatic disease. The patient 
was staged at IVB, and the case was subsequently discussed at a Multidisciplinary tumor 
board given the complex nature of the case. Due to the proximity of critical structures, the 
patient was deemed unresectable at the time. Given the large tumor burden and locally ad-
vanced disease, the decision was made to proceed with Neo-adjuvant chemotherapy, with the 
eventual plan for surgical resection with additional chemotherapy and radiation as needed. 
The patient was initiated on Docetaxel/Cisplatin/5 FU (TPF) the same week, and completed 3 
cycles without complication. The patient noted significant clinical improvement in vision, di-
plopia and headaches during this period. The 4th cycle was completed but given without 
Docetaxel due to hepatotoxicity. 
Repeat MRI Brain in late August 2018 showed an interval decrease in the size of the pre-
viously described sinonasal lesion now measuring approximately 4.2 × 4.1 × 3.2 cm (AP, TR, 
SI), previously 5 × 4.5 × 4.5 cm (AP, TR, SI). Aspects of the mass lesion had improved 
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significantly with decreased extension into the left medial orbital wall, left orbital apex and 
left posterior ethmoidal air cells and sphenoidal sinus, and there was near complete resolution 
of the mass effect on the left optic nerve and bilateral medial rectus muscles (Fig. 2). Unfortu-
nately, the patient returned to the ER in late September 2018 with symptoms of a headache 
associated with nausea and vomiting. Initial CT Head showed mild interval increase, but an 
MRI in the next couple weeks showed a more substantial interval increase in size of sinonasal 
tumor with progression of intracranial tumor extension now involving the cavernous sinuses 
and frontal fossae. The initial Neurosurgical plan for resection was aborted in setting of such 
aggressive progression seen on imaging. Most recently, the patient was initiated on concur-
rent chemo-radiation with Cisplatin, with an interval MRI brain showing again an interval de-
crease in the size of his sinonasal tumor with diminished mass effect on the orbital contents, 
cavernous sinuses and frontal fossae. 
Discussion 
SNUC is a poorly differentiated and aggressive disease with limited consensus on optimal 
management due to the rarity of the disease. The disease is characterized by a high mitotic 
rate, tumor necrosis, prominent vascular permeation, and absence of glandular differentia-
tion. It is immunohistochemically distinct from other sinonasal malignancies such as lym-
phoma, neuroendocrine carcinoma, mucosal melanoma, nasopharyngeal carcinoma, and ol-
factory neuroblastoma. Cytokeratin staining is positive while staining for leucocyte common 
antigen (LCA), S-100 protein, vimentin, in situ hybridization for Ebstein-Barr encoded RNA 
(EBER), synaptophysin and calretinin are generally negative [5]. Tumors are typically ad-
vanced at presentation with 70–100% of tumors being T4 and 10–30% of tumors having in-
volved neck nodes [6]. Long term survival rates range from 20–40% with tumor stage being 
an independent predictor of survival [4, 7]. Symptoms are usually of short duration (weeks to 
months) contrasting with the gradual onset associated with other sinonasal tract neoplasms.  
Our case demonstrates the use of TPF followed by concurrent Cisplatin with radiation in 
a young otherwise healthy individual diagnosed with locally advanced, unresectable SNUC. 
Studies have shown that an aggressive multimodality approach involving combinations of sur-
gery, chemotherapy, and/or radiation is recommended given the high likelihood of local re-
currence, generally advanced stage at presentation, and proximity to critical structures [4, 5, 
8]. Trimodality was evaluated by Mourad et al. in single institution retrospective study of 18 
patients with sinonasal undifferentiated carcinoma. Neoadjuvant chemotherapy included TPF 
every 3 weeks for 2 to 3 cycles. In all patients receiving concurrent chemoradiation, cisplatin 
was used at a dose of 100 mg/m2 every 3 weeks for 3 cycles. The trimodality approach pro-
vided 83% Local Control (LC) and 33% Distant Metastases-Free (DM) survival whereas other 
modalities provided 50% LC and 33% DM-free survival. In Guo et al., 41 patients with Stage 
III or IV nasopharyngeal cancer were treated with TPF, with limited adverse effects, so the 
regimen was deemed a safe and effective way to treatment advanced disease. Morand et al. 
performed a case-series, systematic review and meta-analysis of the data involving treatment 
modalities for patients with SNUC, evaluating a total of 390 patients. 80% of patients pre-
sented with a T4 tumor and 16% with nodal metastases at diagnosis. Single modality treat-
ment (surgery or radiation alone) was associated with reduced survival compared to double 
modality (surgery and radiation or chemoradiation). In this specific study it was noted that 
trimodality was not superior to double modality [5, 8]. 
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Conclusion 
Based off of literature review and prior case series, the multiple modality approach 
should result in the best possible outcome for this rare and aggressive disease [4, 5, 9]. In this 
specific case of a young Hispanic male with Stage IVB SNUC, we proceeded with Neoadjuvant 
TPF with effective results, followed by Cisplatin and concurrent radiation once the patient had 
interval progression, and was deemed unresectable. Given the rarity and complexity of this 
disease, a prospective randomized controlled study should eventually be pursued to properly 
determine the most effective mode and combination of therapies. At this time treatment can 
only be based on reported case series and a small number of retrospective studies, and there-
fore it is important to continue to evaluate different institutions’ methods of treatment. 
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Fig. 1. MRI orbit 5/2018. 5.2 × 4.3 × 4.2 cm (AP, TR, SI) T1/T2 isointense mass lesion with mildly hetero-
geneous enhancement and diffusion restriction centered at posterior ethmoidal air cells, and extension 
into posterior cerebral nasal cavity including superior turbinates, sphenoidal sinuses, bilateral orbital me-
dial walls and anterior cranial fossa. 
 
 
 
Fig. 2. MRI Orbit 8/2018. Since 05/30/2018, interval decrease in the size of the previously described si-
nonasal lesion now measuring approximately 4.2 × 4.1 × 3.2 cm (AP, TR, SI), previously 5 × 4.5 × 4.5 cm 
(AP, TR, SI). Left aspect of the mass lesion has decreased significantly with decreased extension into the 
left medial orbital wall, left orbital apex and left posterior ethmoidal air cells and sphenoidal sinus. Near 
complete resolution of the mass effect on the left optic nerve and bilateral medial rectus muscles. 
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Fig. 3. Pathology slides for Patient TV confirming Sinonasal Undifferentiated Carcinoma. 
 
